Replies to post #171419 on Biotech Values

[Biowatch]

OT: XON was Exxon's ticker before Exxon/Mobile became XOM

Pretty prestigious ticker for such a new company. I wonder if people will accidentally mix up XON and XOM when trading?

[ghmm]

XON / MEDS:

Intrexon to Acquire Medistem to Generate Multipotent Cells


Medistem's Stem Cell Technology to be Integrated Into Intrexon's Proprietary Synthetic Biology Platform

http://finance.yahoo.com/news/intrexon-acquire-medistem-generate-multipotent-154433543.html

I don't follow Intrexon and don't really know what Kirk means by synthetic biology sure seems he has done a wide array of (albeit smaller) deals I don't follow the connection(s) though.

...to acquire, for approximately $26 million, San Diego-based Medistem, Inc. (MEDS) a pioneer in the development of Endometrial Regenerative Cells ... Pursuant to the definitive agreement, Medistem stockholders will receive in exchange for each share of Medistem common stock $0.27 in cash and $1.08 worth of Intrexon common stock, based on the 20-day volume-weighted average price of Intrexon's common stock immediately prior to closing.

[DewDiligence]

HALO borrows additional $20M from banks:

http://www.sec.gov/Archives/edgar/data/1159036/000115903614000002/a8-k_halo27dec2013.htm

On December 27, 2013, Halozyme Therapeutics, Inc…entered into an Amended and Restated Loan and Security Agreement with Oxford Finance LLC…and Silicon Valley Bank...

The Original Loan Agreement provided for a $30 million secured single-draw term loan facility with a maturity date of January 1, 2017. The original term loan was fully drawn at close [in Dec 2012].

The [amended] Loan Agreement extends the original $30 million term loans and provides for an additional $20 million in new term loans, bringing the total term loan balance to $50 million. Upon closing of the Loan Agreement, the Company received approximately $19 million, net of accrued interest.

[DewDiligence]

(HALO)—CHMP approves Roche’s MabThera SC (subcutaneous):

http://www.prnewswire.com/news-releases/halozyme-announces-positive-opinion-from-chmp-for-european-approval-of-roches-mabthera-sc-241828341.html